演題詳細

ポスター / Poster

ポスター 21 (Poster 21) :LPD/免疫不全・高齢者

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
岡 芳弘 (Yoshihiro Oka):1
1:大阪大学大学院医学系研究科 呼吸器・免疫アレルギー内科学
 
前へ戻る

Non-Hodgkin's lymphoma in elderly patients aged 80 years or older

演題番号 : PS-1-156

逸見 麻衣 (Mai Henmi):1、牧田 雅典 (Masanori Makita):1、清家 圭介 (Keisuke Seike):1、三道 康永 (Yasuhisa Sando):1、石川 立則 (Tatsunori Ishikawa):1、原 嘉孝 (Yoshitaka Hara):1、山本 和彦 (Kazuhiko Yamamoto):1、今城 健二 (Kenji Imajo):1

1:Department of Hematology and Oncology, Okayama City Hospital

 

BACKGROUND: One half of Non-Hodgkin's lymphoma (NHL) occur in patients older than 65 years and NHL in patients older than 80 years is not a rare disease. However, very few, if any, studies reported data on these patients. Among 208 patients with newly diagnosed NHL between January 2006 and December 2011 in our institution, we herein evaluated 38 patients aged 80 years or older in a retrospective analysis. RESULTS: The median age was 83 years (range 80-96, 17 males and 21 females). The most frequent histological features were diffuse large B-cell lymphoma (68%) and T-cell subtype cases were 6 (16%). Thirty one of the 38 patients (81%) were in disseminated stage and 22 (58%) had B symptoms. Twenty two patients (58%) had poor performance status (PS) of 2-4. The majority (86%) received THP-COP regimen with a dose reduction. Overall response rate was 84% and the median survival time was 36.9 months and the main cause of death was NHL progression (64%), while treatment-related death was observed in 6 patients mainly consisting of infection. A univariate analysis showed significant differences in the sex (P = .019), B symptoms (P = .009) and PS (P = .000) between the two groups aged younger or older than 80, and patients older than 80 years tended to have an inferior overall survival (median 36.9 versus 65.1 months, P = .056). CONCLUSIONS: NHL patients older than 80 years had advanced disease and a poor prognosis compared with younger than 80, moreover the risk of treatment-related death is high. An effective therapy regimen for these patients needs to be established.

前へ戻る